187 related articles for article (PubMed ID: 18759326)
1. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
Overman MJ; Kopetz S; Wen S; Hoff PM; Fogelman D; Morris J; Abbruzzese JL; Ajani JA; Wolff RA
Cancer; 2008 Oct; 113(8):2038-45. PubMed ID: 18759326
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Horimatsu T; Nakayama N; Moriwaki T; Hirashima Y; Fujita M; Asayama M; Moriyama I; Nakashima K; Baba E; Kitamura H; Tamura T; Hosokawa A; Yoshimura K; Muto M
Int J Clin Oncol; 2017 Oct; 22(5):905-912. PubMed ID: 28536826
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy in advanced small bowel adenocarcinoma.
Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).
Aydin D; Sendur MA; Kefeli U; Umut Unal O; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Bala Ustaalioglu B; Sener Dede D; Esbag O; Inal A; Bilir C; Bilici A; Harputlu H; Berk V; Sevinc A; Yildirim Ozdemir N; Yildirim E; Sonkaya A; Ali Ustaoglu M; Gumus M
J BUON; 2016; 21(5):1242-1249. PubMed ID: 27837629
[TBL] [Abstract][Full Text] [Related]
5. Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.
Nakazawa T; Narita Y; Kumanishi R; Ogata T; Matsubara Y; Nozawa K; Kato K; Honda K; Masuishi T; Bando H; Kadowaki S; Ando M; Hara K; Tajika M; Muro K
Anticancer Res; 2021 Oct; 41(10):5147-5155. PubMed ID: 34593466
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
Li X; Ying H; Cheng Y; Zhao L; Zhao S; Bai C; Zhou J
J BUON; 2019; 24(6):2539-2545. PubMed ID: 31983130
[TBL] [Abstract][Full Text] [Related]
7. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
8. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
10. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
Huffman BM; Jin Z; Yadav S; Patel S; Nagorney DM; Truty MJ; McWilliams RR; Halfdanarson TR; Mahipal A
Clin Colorectal Cancer; 2019 Sep; 18(3):218-225. PubMed ID: 31178274
[TBL] [Abstract][Full Text] [Related]
11. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
Zhang L; Wang LY; Deng YM; Wang FH; Feng F; Chen YC; An X; Chen C; Xu RH; Li YH
J BUON; 2011; 16(4):689-96. PubMed ID: 22331723
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
Aydin D; Sendur MA; Kefeli U; Unal OU; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Ustaalioglu BB; Uysal M; Esbag O; Yazilitas D; Tanrıverdi O; Bilici A; Arpaci E; Berk V; Yetisyigit T; Ozdemir NY; Oztop I; Alacacioglu A; Aydin O; Ozcelik M; Yildirim E; Dinc N; Gumus M
Clin Colorectal Cancer; 2017 Sep; 16(3):220-227. PubMed ID: 27670893
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
15. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy.
Bhamidipati D; Colina A; Hwang H; Wang H; Katz M; Fournier K; Serpas V; Thomas J; Sun R; Wolff RA; Raghav K; Overman MJ
ESMO Open; 2021 Jun; 6(3):100132. PubMed ID: 33940348
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
Overman MJ; Kopetz S; Lin E; Abbruzzese JL; Wolff RA
Acta Oncol; 2010 May; 49(4):474-9. PubMed ID: 20397775
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
[TBL] [Abstract][Full Text] [Related]
18. A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.
Makino S; Takahashi H; Haraguchi N; Nishimura J; Hata T; Matsuda C; Ikenaga M; Murata K; Yamamoto H; Doki Y; Mori M; Mizushima T
Anticancer Res; 2017 Mar; 37(3):1495-1500. PubMed ID: 28314324
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Zaanan A; Costes L; Gauthier M; Malka D; Locher C; Mitry E; Tougeron D; Lecomte T; Gornet JM; Sobhani I; Moulin V; Afchain P; Taïeb J; Bonnetain F; Aparicio T
Ann Oncol; 2010 Sep; 21(9):1786-1793. PubMed ID: 20223786
[TBL] [Abstract][Full Text] [Related]
20. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Tsushima T; Taguri M; Honma Y; Takahashi H; Ueda S; Nishina T; Kawai H; Kato S; Suenaga M; Tamura F; Morita S; Boku N
Oncologist; 2012; 17(9):1163-70. PubMed ID: 22622149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
